Daxor (DXR) Fundamentals 2026 — P/E 5.7x, Revenue Analysis | SniperIQ

0.41 on the NASDAQ. This SniperIQ fundamentals page covers Daxor's valuation (P/E 5.7x, P/B 1.1x), profitability (net margin 6105.3%), revenue ($503,424 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Daxor's market cap?

Daxor (DXR) has a market capitalization of approximately $52M, trading at

0.41 on the NASDAQ. Market cap moves with the live share price.

What is Daxor's P/E ratio?

Daxor's trailing twelve-month P/E ratio is 5.7x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Daxor?

Daxor runs a net profit margin of 6105.3%, a gross margin of -57.5%, and an operating margin of 6174.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Daxor generate?

Daxor reported revenue of $503,424 for fiscal year 2025, with net income of $9M and earnings per share (EPS) of 1.84. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Daxor pay a dividend?

Daxor does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Daxor financially healthy?

Daxor carries a debt-to-equity ratio of 0.00x and a current ratio of 0.00x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Daxor a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Daxor (DXR) the key facts are: market cap $52M, P/E 5.7x, revenue $503,424, 52-week range 8.56-14.76. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.